Condition

Hormone Receptor Positive Tumor clinical trials and research

• 10Clinical trials
• 29Countries

Newest Hormone Receptor Positive Tumor clinical trials

All recruiting trials (10)

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

• TheraBionic P1 device in advanced HR-positive, HER2-negative breast cancer

  This trial tests whether the TheraBionic P1 device can help women with advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed on standard therapies, by looking at survival and disease control.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Bay City, Michigan and 7 other locations · NCT07227831

• Adding TheraBionic P1 radiofrequency therapy to treatment for early-stage HR+ HER2- breast cancer

  This study will try giving TheraBionic P1 amplitude-modulated radiofrequency therapy before surgery to see if it improves tumor response in women with early-stage, hormone receptor–positive, HER2-negative breast cancer.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Clarkston, Michigan and 7 other locations · NCT07218432

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• How well patients stick to aromatase inhibitor treatment, with or without abemaciclib, for early HR+/HER2- breast cancer

  This study tests whether people with early HR+/HER2- breast cancer stick to aromatase inhibitor treatment more or less when they also take abemaciclib.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT06650423

• Elacestrant alone or with triptorelin for premenopausal luminal (HR+/HER2−) breast cancer

  This trial will test whether the oral drug elacestrant, given alone or with triptorelin (and compared to tamoxifen in Part B), changes tumor biology in premenopausal women with operable hormone receptor–positive, HER2‑negative breast cancer.

  Recruiting at 15 sites Phase 2 SOLTI Breast Cancer Research Group · Badalona, Barcelona and 14 other locations · NCT05982093

• Evaluating INX-315 for advanced cancer treatment

  This study is testing a new oral medication called INX-315 to see if it can safely help people with advanced cancers, including breast and ovarian cancer, who haven't responded to other treatments.

  Recruiting at 17 sites Phase 1/2 Incyclix Bio · Orlando, Florida and 17 other locations · NCT05735080

• Precision therapy for advanced breast cancer patients

  This study is testing different targeted treatments for patients with advanced breast cancer who have already tried certain medications, to see if personalized options can help them feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05594095

• Precision neoadjuvant therapy for operable breast cancer

  This study is testing if a personalized treatment approach using new drugs for operable breast cancer can work better than standard chemotherapy alone.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05582499

• Personalized treatment for breast cancer using new drug agents

  This study is testing new drug combinations with standard chemotherapy to see which treatments work best for different types of breast cancer based on the specific characteristics of each patient's tumor.

  Recruiting at 32 sites Phase 2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 41 other locations · NCT01042379

Related topics

Quick answers

How many Hormone Receptor Positive Tumor clinical trials are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 29 countries. The most sites are in United States (6 trials), Australia (2 trials), China (2 trials), Spain (2 trials), Slovenia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 1, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →